Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Katrina Sondermann et al.|New England Journal of Medicine|2019Cited by 502
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R. Brown, Mazyar Shadman, Barbara Eichhorst et al.|New England Journal of Medicine|2022Cited by 453
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Michael J. Keating, Deborah A. Thomas et al.|Blood|2003Cited by 254
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemiaAlessandra Ferrajoli, George A. Călin, Tait D. Shanafelt et al.|Blood|2013Cited by 220